March 25, 2024

Santen Announces Cancellation of Treasury Shares

Santen Pharmaceutical Co., Ltd. (Head Office: Osaka; President and CEO: Takeshi Ito) announced that it has resolved at the Board of Directors meeting held on March 25, 2024 to cancel treasury shares as stated below, in accordance with Article 178 of the Companies Act (Japan).

1. Class of shares to be canceled:

Common shares

2. Total number of shares to be canceled:

12,000,000 shares

(The ratio against total number of the outstanding

shares before the Cancellation: 3.2%)

3. Scheduled date of cancellation:

March 29, 2024

Note

  • (1) The total number of the outstanding shares of the Company (including its treasury shares) after the Cancellation is expected to be 363,992,354 shares.

  • (2) The number of treasury shares after the Cancellation is expected to be 737,469 shares.

Contact:

Guillaume Sakuma

Global Head of IR, IR Group E-mail:ir@santen.com

About Santen

As a specialized company dedicated to eye health, Santen aspires to contribute to the realization of "Happiness with Vision" by providing products and services to patients, consumers, and medical professionals around the world. Since its establishment, and guided by its CORE PRINCIPLE, "Tenki ni sanyo suru," Santen has been committed to helping people maintain and improve their eye health for more than 130 years. Santen is engaged in the global research and development, manufacturing, and sales and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries and regions worldwide. Santen's mission is to provide essential and significant value to patients and society in the prevention, diagnosis, and treatment of eye diseases through products and services created from its expertise in the ophthalmology field and from the patient's perspective. To create a future in which as many patients as possible can lead happy and fulfilling lives, Santen is committed to doing its utmost to realize a society in which people around the world can experience "Happiness with Vision."

For more information, please visit Santen's websitehttps://www.santen.com/en.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Santen Pharmaceutical Co. Ltd. published this content on 25 March 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 25 March 2024 07:06:08 UTC.